4.7 Article

Safety of investigative bronchoscopy in the Severe Asthma Research Program

期刊

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
卷 128, 期 2, 页码 328-U339

出版社

MOSBY-ELSEVIER
DOI: 10.1016/j.jaci.2011.02.042

关键词

Investigative bronchoscopy; safety; severe asthma; exacerbation

资金

  1. NHLBI
  2. National Institutes of Health (NIH)/NHLBI
  3. NIH-NIAID
  4. Novartis
  5. AstraZeneca
  6. GlaxoSmithKline
  7. MedImmune
  8. Ception
  9. Asthmatx
  10. Amgen
  11. Genentech
  12. Merck
  13. NIH
  14. Elsevier
  15. state of Ohio
  16. Aerovance
  17. Ception Therapeutics
  18. Icagen
  19. [HL69116]
  20. [HL69130]
  21. [HL69155]
  22. [HL69167]
  23. [HL69170]
  24. [HL69174]
  25. [HL69349]
  26. [HL091762]
  27. [M01 RR03186]
  28. [M01 RR007122-14]
  29. [1UL1RR024992]
  30. [1UL1RR024989]
  31. [1UL1RR025011]
  32. Medical Research Council [G1000758, G1000758B] Funding Source: researchfish
  33. National Institute for Health Research [NF-SI-0508-10212] Funding Source: researchfish

向作者/读者索取更多资源

Background: Investigative bronchoscopy was performed in a subset of participants in the Severe Asthma Research Program to gain insights into the pathobiology of severe disease. We evaluated the safety aspects of this procedure in this cohort with specific focus on patients with severe asthma. Objective: To evaluate prospectively changes in lung function and the frequency of adverse events related to investigative bronchoscopy. Methods: Bronchoscopy was performed by using a common manual of procedures. A subset of very severe asthma was defined by severe airflow obstruction, chronic oral corticosteroid use, and recent asthma exacerbations. Subjects were monitored for changes in lung function and contacted by telephone for 3 days after the procedure. Results: A total of 436 subjects underwent bronchoscopy (97 normal, 196 not severe, 102 severe, and 41 very severe asthma). Nine subjects were evaluated in hospital settings after bronchoscopy; 7 of these were respiratory-related events. Recent emergency department visits, chronic oral corticosteroid use, and a history of pneumonia were more frequent in subjects who had asthma exacerbations after bronchoscopy. The fall in FEV1 after bronchoscopy was similar in the severe and milder asthma groups. Prebronchodilator FEV1 was the strongest predictor of change in FEV1 after bronchoscopy with larger decreases observed in subjects with better lung function. Conclusion: Bronchoscopy in subjects with severe asthma was well tolerated. Asthma exacerbations were rare, and reduction in pulmonary function after the procedure was similar to that in subjects with less severe asthma. With proper precautions, investigative bronchoscopy can be performed safely in severe asthma. (J Allergy Clin Immunol 2011;128:328-36.)

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据